Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center GlobeNewswire - Wed Jun 25, 8:00AM CDT

APRE : 1.7700 (-5.85%)
Aprea Therapeutics
Artios' AACR Data Success: What It Means for Aprea Therapeutics' ATRN-119 Program Barchart Impact - Tue Jun 10, 10:01AM CDT

Discover how Artios Pharma's "game-changing" ATR inhibitor trial success validates this cancer treatment strategy, boosting prospects for Aprea Therapeutics' similar drug and offering hope for ATM-deficient...

APRE : 1.7700 (-5.85%)
Aprea Therapeutics
This Under-The-Radar Cancer Biotech Reports 21% Tumor Shrinkage: Analysts See 600%+ Upside Barchart Impact - Wed May 14, 3:17PM CDT

A clinical-stage biotech company focused on synthetic lethality has reported promising progress across its cancer drug pipeline, highlighted by early signs of tumor reduction in multiple patients, with...

APRE : 1.7700 (-5.85%)
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update GlobeNewswire - Wed May 14, 7:00AM CDT

APRE : 1.7700 (-5.85%)
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial GlobeNewswire - Mon Mar 31, 7:30AM CDT

APRE : 1.7700 (-5.85%)
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update GlobeNewswire - Tue Mar 25, 7:30AM CDT

APRE : 1.7700 (-5.85%)
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) GlobeNewswire - Tue Mar 11, 7:30AM CDT

APRE : 1.7700 (-5.85%)
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics GlobeNewswire - Wed Feb 5, 7:00AM CST

APRE : 1.7700 (-5.85%)
Aprea Therapeutics Initiates Twice Daily Dosing of ATRN-119 in Phase 1/2a Clinical Trial to Enhance Cancer Treatment Efficacy Quiver Quantitative, Inc. - Wed Dec 11, 2024

Aprea Therapeutics initiates twice daily dosing of ATRN-119 in cancer trial to enhance efficacy and optimize patient outcomes.Quiver AI SummaryAprea Therapeutics has initiated a twice daily dosing regimen...

APRE : 1.7700 (-5.85%)
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward GlobeNewswire - Wed Dec 11, 2024

APRE : 1.7700 (-5.85%)

Barchart Exclusives

Intel Is Kicking Off a Major Layoffs Push. What Do the Job Cuts Mean for INTC Stock? Barchart - 1 hour ago
Intel’s sweeping layoffs highlight a dramatic push to cut costs and streamline operations as it battles to reclaim lost market share. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot